AJAndrew J. Jezewski

Andrew J. Jezewski

*This is an algorithmically generated author record based on publicly available information.

Andrew J. Jezewski has a total of 87 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Optimization of Antifungal 1,5-Diaryl-Pyrazole Acetyl-CoA Synthetase Inhibitors

    by Jonah P. Propp, Jeffrey C. Ferreira, Parisa Enayati, Kathryn M. Alden, Drashti G. Daraji, Charles L. Lail, Michael E. Heene, Andrew J. Jezewski, Rohan Wakade, Damien Castor, et al.

    Acetyl-CoA Synthetases (ACS) have emerged as a potential drug target for the treatment of diseases ranging from fungal and parasitic infections to cancer and hyperlipidemia. While species-selective ACS inhibitors have been reported, broad-spectrum inhibition of ACS enzymes has only been achieved with nucleoside-derived, bisubstrate analogs such as alkyl esters of adenosine monophosphate (AMP). Previously, we identified the diaryl pyrazole AR-12 as a non-nucleoside inhibitor of S. cerevisiae ACS with broad-spectrum antifungal activity. In this study, we undertook a medicinal-chemistry approach to optimize the AR-12 scaffold with the goals of improving its pharmacology and activity against ACS enzymes from human fungal pathogens such as Candida albicans, Cryptococcus neoformans, and Aspergillus fumigatus. These efforts have led to the improved on-target activity for a set of analogs against multiple fungal enzymes. We identified key substituents that are critical determinants of the ACS inhibition displayed by this diaryl pyrazole class of inhibitors. Modeling and molecular dynamics calculations also indicate that these improved molecules likely bind in the same region of the ACS active site in which the alkyl-AMP esters bind. Finally, the most active diaryl pyrazole has improved mammalian cytotoxicity and pharmacology relative to AR-12. However, additional optimization of this class of ACS inhibitors will be needed to generate a molecule with efficacy in preclinical animal models.

  • Open Access

    A single Leishmania adenylate–forming enzyme of the ANL superfamily generates both acetyl- and acetoacetyl-CoA

    by Andrew J. Jezewski, Taiwo E. Esan, Jonah Propp, Andrew J. Fuller, Drashti G. Daraji, Charles Lail, Bart L. Staker, Elijah L. Woodward, Linjun Liu, Kevin P. Battaile, et al.


  • Open Access

    Cryptococcus neoformans adapts to the host environment through TOR-mediated remodeling of phospholipid asymmetry

    by Laura C. Ristow, Andrew J. Jezewski, Benjamin J. Chadwick, Mark A. Stamnes, Xiaorong Lin, Damian J. Krysan

    Cryptococcusspp. are environmental fungi that first must adapt to the host environment before they can cause life-threatening meningitis in immunocompromised patients. Host CO2concentrations are 100-fold higher than the external environment and strains unable to grow at host CO2concentrations are not pathogenic. Using a genetic screening and transcriptional profiling approach, we report that the TOR pathway is critical forC. neoformansadaptation to host CO2partly through Ypk1-dependent remodeling of phosphatidylserine asymmetry at the plasma membrane. We also describe aC. neoformansABC/PDR transporter (PDR9) that is highly expressed in CO2-sensitive environmental strains, suppresses CO2-induced phosphatidylserine/phospholipid remodeling, and increases susceptibility to host concentrations of CO2. Interestingly, regulation of plasma membrane lipid asymmetry by the TOR-Ypk1 axis is distinct inC. neoformanscompared toS. cerevisiae. Finally, host CO2concentrations suppress theC. neoformanspathways that respond to host temperature (Mpk1) and pH (Rim101), indicating that host adaptation requires a stringent balance among distinct stress responses.


  • Open Access

    The fungal pathogen Cryptococcus neoformans adapts to the host environment through TOR-mediated remodeling of phospholipid asymmetry

    by Damian Krysan, Laura Ristow, Andrew Jezewski, Benjamin Chadwick, Mark Stamnes, Xiaorong Lin

    Cryptococcus spp. are environmental fungi that first must adapt to the host environment before they can cause life-threatening meningitis in immunocompromised patients. Host CO2 concentrations are 100-fold higher than the external environment and strains unable to grow at host CO2 concentrations are not pathogenic. Using a genetic screening and transcriptional profiling approach, we found that the TOR pathway is critical for C. neoformans adaptation to host CO2 partly through Ypk1-dependent remodeling of phosphatidylserine asymmetry at the plasma membrane. We also identified a candidate C. neoformans floppase (Lat1) that is highly expressed in CO2-sensitive environmental strains and suppresses CO2-induced phosphatidylserine remodeling. Interestingly, regulation of plasma membrane lipid asymmetry by the TOR-Ypk1 axis is distinct in C. neoformans compared to S. cerevisiae. Finally, host CO2 concentrations suppress the C. neoformans pathways that respond to host temperature (Mpk1) and pH (Rim101), indicating that host adaptation requires a stringent balance among distinct stress responses.

  • Open Access

    GAPDH cooperativity mediates drug resistance and metabolism in Plasmodium fal-ciparum malaria parasites

    by Andrew J. Jezewski, Ann M. Guggisberg, Dana M. Hodge, Naomi Ghebremichael, Lisa K. McLellan, Audrey R. Odom John

    Efforts to control the global malaria health crisis are undermined by antimalarial resistance. Iden-tifying mechanisms of resistance will uncover the underlying biology of the Plasmodium falciparum malaria parasites that allow evasion of our most promising therapeutics and may reveal new drug targets. We utilized fosmidomycin (FSM) as a chemical inhibitor of plastidial isoprenoid biosynthesis through the methylerythritol phosphate (MEP) pathway. We have thus identified an unusual metabolic regulation scheme in the malaria parasite through the essential glycolytic enzyme, glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Two parallel genetic screens converged on independent but functionally analogous resistance alleles in GAPDH. Metabolic profiling of FSM-resistant gapdh mutant parasites indicates that neither of these mutations disrupt overall glycolytic output. While FSM-resistant GAPDH variant proteins are catalytically active, they have reduced assembly into the homotetrameric state favored by wild-type GAPDH. Disrupted oligomerization of FSM-resistant GAPDH variant proteins is accompanied by altered enzymatic cooperativity and reduced susceptibility to inhibition by free heme. Together, our data identifies a new genetic biomarker of FSM-resistance and reveals the central role of GAPDH cooperativity in MEP pathway control and antimalarial sensitivity.

  • Open Access

    Targeting host glycolysis as a strategy for antimalarial development

    by Andrew J. Jezewski, Yu-Hsi Lin, Julie A. Reisz, Rachel Culp-Hill, Yasaman Barekatain, Victoria C. Yan, Angelo D’alessandro, Florian L. Muller, Audrey R. Odom John

    Glycolysis controls cellular energy, redox balance, and biosynthesis. Antiglycolytic therapies are under investigation for treatment of obesity, cancer, aging, autoimmunity, and microbial diseases. Interrupting glycolysis is highly valued as a therapeutic strategy, because glycolytic disruption is generally tolerated in mammals. Unfortunately, anemia is a known dose-limiting side effect of these inhibitors and presents a major caveat to development of antiglycolytic therapies. We developed specific inhibitors of enolase – a critical enzyme in glycolysis – and validated their metabolic and cellular effects on human erythrocytes. Enolase inhibition increases erythrocyte susceptibility to oxidative damage and induces rapid and premature erythrocyte senescence, rather than direct hemolysis. We apply our model of red cell toxicity to address questions regarding erythrocyte glycolytic disruption in the context of Plasmodium falciparum malaria pathogenesis. Our study provides a framework for understanding red blood cell homeostasis under normal and disease states and clarifies the importance of erythrocyte reductive capacity in malaria parasite growth.


  • Open Access

    Potent, specific MEPicides for treatment of zoonotic staphylococci

    by Rachel L Edwards, Isabel Heueck, Soon Goo Lee, Ishaan T Shah, Justin J Miller, Andrew J Jezewski, Marwa O Mikati, Xu Wang, Robert C Brothers, Kenneth M Heidel, et al.

    Coagulase-positive staphylococci, which frequently colonize the mucosal surfaces of animals, also cause a spectrum of opportunistic infections including skin and soft tissue infections, urinary tract infections, pneumonia, and bacteremia. However, recent advances in bacterial identification have revealed that these common veterinary pathogens are in fact zoonoses that cause serious infections in human patients. The global spread of multidrug-resistant zoonotic staphylococci, in particular the emergence of methicillin-resistant organisms, is now a serious threat to both animal and human welfare. Accordingly, new therapeutic targets that can be exploited to combat staphylococcal infections are urgently needed. Enzymes of the methylerythritol phosphate pathway (MEP) of isoprenoid biosynthesis represent potential targets for treating zoonotic staphylococci. Here we demonstrate that fosmidomycin (FSM) inhibits the first step of the isoprenoid biosynthetic pathway catalyzed by deoxyxylulose phosphate reductoisomerase (DXR) in staphylococci. In addition, we have both enzymatically and structurally determined the mechanism by which FSM elicits its effect. Using a forward genetic screen, the glycerol-3-phosphate transporter GlpT that facilitates FSM uptake was identified in two zoonotic staphylococci, Staphylococcus schleiferi and Staphylococcus pseudintermedius. A series of lipophilic ester prodrugs (termed MEPicides) structurally related to FSM were synthesized, and data indicate that the presence of the prodrug moiety not only substantially increased potency of the inhibitors against staphylococci but also bypassed the need for GlpT-mediated cellular transport. Collectively, our data indicate that the prodrug MEPicides selectively and robustly inhibit DXR in zoonotic staphylococci, and further, that DXR represents a promising, druggable target for future development. The proliferation of microbial pathogens resistant to the current pool of antibiotics is a major threat to public health. Drug resistance is pervasive in staphylococci, including several species that can cause serious zoonotic infections in humans. Thus, new antimicrobial agents are urgently needed to combat these life-threatening, resistant infections. Here we establish the MEP pathway as a promising new target against zoonotic staphylococci. We determine that fosmidomycin (FSM) selectively targets the isoprenoid biosynthesis pathway in zoonotic staphylococci and use forward genetics to identify the transporter that facilitates phosphonate antibiotic uptake. Employing this knowledge, we synthesized a series of potent antibacterial prodrugs that circumvent the transporter. Together, these novel prodrug inhibitors represent promising leads for further drug development against zoonotic staphylococci.


  • Open Access

    Potent, specific MEPicides for treatment of zoonotic staphylococci

    by Rachel L. Edwards, Isabel Heueck, Soon Goo Lee, Ishaan T. Shah, Andrew J. Jezewski, Justin J. Miller, Marwa O. Mikati, Xu Wang, Robert C. Brothers, Kenneth M. Heidel, et al.

    Coagulase-positive staphylococci, which frequently colonize the mucosal surfaces of animals, also cause a spectrum of opportunistic infections including skin and soft tissue infections, urinary tract infections, pneumonia, and bacteremia. However, recent advances in bacterial identification have revealed that these common veterinary pathogens are in fact, zoonoses that cause serious infections in human patients. The global spread of multidrug-resistant zoonotic staphylococci, in particular the emergence of methicillin-resistant organisms, is now a serious threat to both animal and human welfare. Accordingly, new therapeutic targets that can be exploited to combat staphylococcal infections are urgently needed. Enzymes of the methylerythritol phosphate pathway (MEP) of isoprenoid biosynthesis represent potential targets for treating zoonotic staphylococci. Here we demonstrate that fosmidomycin (FSM) inhibits the first step of the isoprenoid biosynthetic pathway catalyzed by deoxyxylulose phosphate reductoisomerase (DXR) in staphylococci. In addition, we have both enzymatically and structurally determined the mechanism by which FSM elicits its effect. Using a forward genetic screen, the glycerol-3-phosphate transporter GlpT that facilitates FSM uptake was identified in two zoonotic staphylococci, Staphylococcus schleiferi and Staphylococcus pseudintermedius . A series of lipophilic ester prodrugs (termed MEPicides) structurally related to FSM were synthesized, and data indicate that the presence of the prodrug moiety not only substantially increased potency of the inhibitors against staphylococci, but also bypassed the need for GlpT-mediated cellular transport. Collectively, our data indicate that the prodrug MEPicides selectively and robustly inhibit DXR in zoonotic staphylococci, and further, DXR represents a promising, druggable target for future development. Author Summary: The proliferation of microbial pathogens resistant to the current pool of antibiotics is a major threat to public health. Drug resistance is pervasive in staphylococci, including several species that can cause serious zoonotic infections in humans. Thus, new antimicrobial agents are urgently need to combat these life-threatening, resistant infections. Here we establish the MEP pathway as a promising new target against zoonotic staphylococci. We determine that fosmidomycin (FSM) selectively targets the isoprenoid biosynthesis pathway in zoonotic staphylococci, and use forward genetics to identify the transporter that facilitates phosphonate antibiotic uptake. Employing this knowledge, we synthesized a series of potent antibacterial prodrugs that circumvent the transporter. Together, these novel prodrug inhibitors represent promising leads for further drug development against zoonotic staphylococci.

  • Helminth infection reactivates latent γ-herpesvirus via cytokine competition at a viral promoter

    by T. A. Reese, B. S. Wakeman, H. S. Choi, M. M. Hufford, S. C. Huang, X. Zhang, M. D. Buck, A. Jezewski, A. Kambal, C. Y. Liu, et al.

    Parasites make it hard to fight viruses: Microbial co-infections challenge the immune system—different pathogens often require different flavors of immune responses for their elimination or containment (see the Perspective by Maizels and Gause). Two teams studied what happens when parasitic worms and viruses infect mice at the same time. Reese et al. found that parasite co-infection woke up a dormant virus. Osborne et al. found that mice already infected with parasitic worms were worse at fighting off viruses. In both cases, worms skewed the immune response so that the immune cells and the molecules they secreted created an environment favorable for the worm at the expense of antiviral immunity. Science , this issue p. 573 and p. 578 ; see also p. 517


  • A novel method for simulating insulin mediated GLUT4 translocation

    by Andrew J. Jezewski, Joshua J. Larson, Beata Wysocki, Paul H. Davis, Tadeusz Wysocki

    Glucose transport in humans is a vital process which is tightly regulated by the endocrine system. Specifically, the insulin hormone triggers a cascade of intracellular signals in target cells mediating the uptake of glucose. Insulin signaling triggers cellular relocalization of the glucose transporter protein GLUT4 to the cell surface, which is primarily responsible for regulated glucose import. Pathology associated with the disruption of this pathway can lead to metabolic disorders, such as type II diabetes mellitus, characterized by the failure of cells to appropriately uptake glucose from the blood. We describe a novel simulation tool of the insulin intracellular response, incorporating the latest findings regarding As160 and GEF interactions. The simulation tool differs from previous computational approaches which employ algebraic or differential equations; instead, the tool incorporates statistical variations of kinetic constants and initial molecular concentrations which more accurately mimic the intracellular environment. Using this approach, we successfully recapitulate observed in vitro insulin responses, plus the effects of Wortmannin‐like inhibition of the pathway. The developed tool provides insight into transient changes in molecule concentrations throughout the insulin signaling pathway, and may be employed to identify or evaluate potentially critical components of this pathway, including those associated with insulin resistance. In the future, this highly tractable platform may be useful for simulating other complex cell signaling pathways. Biotechnol. Bioeng. 2014;111: 2454–2465.